Concerns have arisen regarding the disclosure management of KOSDAQ-listed companies, as they have delayed important information related to clinical trials for over two months and withdrawn previously announced merger plans. The failure to timely disclose or retract significant management information could lead to confusion among investors.
According to the Korea Exchange on the 20th, Imunonsia and Hengsheng Group were designated as companies with incomplete disclosures. The exchange announced the designation of the two companies after the market closed the previous day. The total fines imposed for disclosure violations on the two companies amount to 20 million won (KRW). On the same day, warnings were issued for Aribio Holdings and Crowdworks regarding their potential designation as companies with incomplete disclosures.
Imunonsia was found to have delayed the disclosure of two significant management matters related to changes in its clinical trial plan. The approval application for the change, which occurred on July 1, and the approval details from August 4 were only disclosed on September 14. The first matter was delayed by over two months, while the second was delayed by more than a month.
The exchange assessed four penalty points for the two instances of non-disclosure but replaced this with a fine of 16 million won (KRW). Consequently, the final penalty points were recorded as zero.
Hengsheng Group was also designated as a company with incomplete disclosures due to delays in announcing matters related to the inclusion and withdrawal of its subsidiaries. The fine imposed on the company for disclosure violations is 4 million won (KRW). This highlights the importance of timely communication regarding changes in corporate governance.
There have also been instances where previously announced management decisions were retracted or the accuracy of disclosures was questioned. Aribio Holdings is facing a warning for designation as a company with incomplete disclosures due to the retraction of its merger decision. Since mergers are significant management matters that can affect corporate value and governance, such retractions could create confusion in investment decisions.
Crowdworks has also been warned for potentially being designated as a company with incomplete disclosures due to falsely announcing the method of financing during the process of changing its largest shareholder. Both companies are still awaiting final sanctions, with the designation expected to be decided on the 14th of next month.
Incomplete disclosures occur when a listed company fails to fulfill its disclosure obligations or retracts or changes previously disclosed information. The exchange imposes penalties or fines based on the severity of the violations, and accumulated penalty points can lead to additional market actions.
Particularly, information related to clinical trials, mergers, and changes in the largest shareholder can significantly impact corporate value and stock prices. Delayed disclosures can create information gaps among investors, and repeated retractions of major management decisions can erode trust in the company.
A securities industry official stated, "Disclosures are fundamental information for investors to assess a company's value, so accuracy and timeliness are crucial. If delays or retractions in disclosures regarding major management matters continue, trust in the company may be undermined, necessitating the strengthening of internal disclosure management systems."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.